MINNEAPOLIS, Dec. 20, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for its ...

At Thermo Fisher Scientific, our goal is to bring innovative new products and services that enable the development of more physiologically relevant disease models to help accelerate the drug discovery ...

DUBLIN--(BUSINESS WIRE)--The "Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, & Forecasts, 2025" report has been added to ResearchAndMarkets.com's offering. Since the ...

HAMBURG, GERMANY, AND TORONTO, ON / ACCESSWIRE / April 2, 2020 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the innovative biotechnology company panCELLa Inc.

Induced pluripotent stem cells (iPSCs) are opening new avenues to expand the number of patients who can benefit from cell therapies. Currently, most advanced cell therapies are autologous. Cells are ...

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Cellistic, a cell therapy platform provider that partners with therapeutic developers to ensure cell therapies can achieve their full potential, has ...

PHILADELPHIA, March 3, 2021 /PRNewswire/ -- Century Therapeutics, a leading cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today ...

FT819 Off-the-Shelf CAR T-cell Product Candidate Derived from Clonal Engineered Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus Interim Phase 1 Dose-escalation Data ...

SereNeuro Therapeutics, a preclinical biotechnology company developing non-opioid pain therapies, unveiled new data today on a novel approach to chronic pain management and joint tissue preservation.

A new stem cell–based therapy challenges traditional pain treatment by using pain-sensing neurons to reduce inflammation and protect joints. Newly released preclinical data describes an unconventional ...

Phase 1 Clinical Study to Evaluate Multiple Doses of FT538 as Monotherapy for Acute Myeloid Leukemia and in Combination with Anti-CD38 Monoclonal Antibody Therapy for Multiple Myeloma Off-the-shelf NK ...